Suppr超能文献

著名医学期刊上主要心血管随机临床试验中复合终点使用的时间趋势。

Temporal Trends in Use of Composite End Points in Major Cardiovascular Randomized Clinical Trials in Prominent Medical Journals.

作者信息

Tan Nigel S, Ali Sammy H, Lebovic Gerald, Mamdani Muhammad, Laupacis Andreas, Yan Andrew T

机构信息

From the Terrence Donnelly Heart Centre, Department of Medicine, St Michael's Hospital (N.S.T., A.T.Y.), Applied Health Research Centre, Keenan Research Centre, Li Ka Shing Knowledge Institute, St Michael's Hospital (G.L.), Institute of Health Policy, Management and Evaluation (G.L., M.M., A.L.), The Leslie Dan Faculty of Pharmacy (M.M.), and Li Ka Shing Knowledge Institute, St Michael's Hospital (M.M., A.L.), University of Toronto, Canada; and Department of Medicine, St Mary's General Hospital, Kitchener, Canada (S.H.A.).

出版信息

Circ Cardiovasc Qual Outcomes. 2017 Oct;10(10). doi: 10.1161/CIRCOUTCOMES.117.003753.

Abstract

BACKGROUND

Cardiovascular mortality has decreased over the past 5 decades, making it increasingly difficult to demonstrate significant benefits of new therapies in randomized clinical trials. We sought to determine whether the use of composite end points in major cardiovascular trials has changed over time and examine temporal trends in the clinical importance of individual components of these composite end points.

METHODS AND RESULTS

Using a validated search strategy, we searched MEDLINE for randomized trials of therapies for primary or secondary cardiovascular prevention published in , , and the between 1986 and 2015. We abstracted and categorized study population demographics, type of intervention, and primary and secondary outcomes. Composite end point components were ranked according to importance (minor, moderate, major, critical, and death) and temporal trends analyzed. In total, 604 of 2607 trials retrieved met inclusion criteria. Use of composite end points increased significantly over time from 18.8% between 1986 and 1990 to 83.0% between 2011 and 2015 (<0.001). The number of components in the primary end point also increased significantly (median 1 in 1986-1990, median 3 in 2011-2015; <0.001). Contemporary trials were more likely to include end points of lesser importance to patients (minor 3.1% and moderate 6.3% in 1986-1990, minor 4.5% and moderate 44.6% in 2011-2015; <0.001). Use of death as the sole primary end point declined significantly over time (53.1% in 1986-1990, 17.9% in 2011-2015; <0.001).

CONCLUSIONS

Contemporary cardiovascular randomized clinical trials are more likely to use primary composite end points that contain a larger number of components. Furthermore, these composite end points have increasingly incorporated components of lesser clinical importance. Clinicians and policymakers interpreting results of randomized trials should recognize that the significance of individual components in a composite end point is often heterogeneous.

摘要

背景

在过去50年中,心血管疾病死亡率有所下降,这使得在随机临床试验中证明新疗法的显著益处变得越来越困难。我们试图确定主要心血管试验中复合终点的使用是否随时间发生了变化,并研究这些复合终点各个组成部分临床重要性的时间趋势。

方法和结果

我们采用经过验证的检索策略,在MEDLINE中检索1986年至2015年期间发表的关于原发性或继发性心血管疾病预防治疗的随机试验。我们提取并分类了研究人群的人口统计学特征、干预类型以及主要和次要结局。根据重要性(轻微、中度、主要、关键和死亡)对复合终点组成部分进行排名,并分析时间趋势。总共检索到的2607项试验中有604项符合纳入标准。复合终点的使用随时间显著增加,从1986年至1990年的18.8%增至2011年至2015年的83.0%(<0.001)。主要终点中的组成部分数量也显著增加(1986 - 1990年中位数为1,2011 - 2015年中位数为3;<0.001)。当代试验更有可能纳入对患者重要性较低的终点(1986 - 1990年轻微终点占3.1%,中度终点占6.3%;2011 - 2015年轻微终点占4.5%,中度终点占44.6%;<0.001)。将死亡作为唯一主要终点的使用随时间显著下降(1986 - 1990年为53.1%,2011 - 2015年为17.9%;<0.001)。

结论

当代心血管随机临床试验更有可能使用包含更多组成部分的主要复合终点。此外,这些复合终点越来越多地纳入了临床重要性较低的组成部分。解读随机试验结果的临床医生和政策制定者应认识到,复合终点中各个组成部分的重要性往往是异质的。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验